AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES, June 7, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO). Class Period:…